Caerus Us 1 Inc. (dba Citeline): Introducing Citeline's Sitetrove Diversity Module, Combining Robust Clinical Investigator and Site Intelligence With Patient Demographics to Support the Diversification of Clinical Trials

NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- With new Food and Drug Administration (FDA) guidance, study sponsors are no longer viewing clinical trial diversity as "nice to have" but as a "must have." Citeline's

Related Keywords

United States ,American ,Citeline Sitetrove ,Dave Laky ,Gewinn Nur ,Drug Administration ,Centers For Medicare Medicaid Services ,Sitetrove Diversity Module ,Diversity Module ,Medicaid Services ,African American ,General Manager ,Caerus ,Citeline ,Ntroducing ,Itetrove ,Diversity ,Module ,Combining ,Obust ,Linical ,Investigator ,Bite ,Intelligence ,Ith ,Patient ,Demographics ,Support ,Diversification ,Trials ,